Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IRF3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IRF3 WT / Phospho-mimetic Mutant (S386D/S396D) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View IRF3 Products |
| Gene Delivery | IRF3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IRF3 Products |
| Benchmark Ab | Anti-IRF3 Antibody Recombinant positive control for western blot/IP. |
View IRF3 Products |
| Validator | IRF3 siRNA Set For knockdown verification. |
View IRF3 Products |
| Related Target A | TBK1 Upstream kinase directly phosphorylating and activating IRF3. |
View TBK1 Products |
| Related Target B | STING Key upstream adaptor in the cGAS-STING-IRF3 innate immune pathway. |
View STING Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Detecting IRF3 activation and nuclear translocation | Lentivirus expressing IRF3-GFP or ISRE-Luciferase reporter for high-throughput live cell screening |
| Screening for dimerization inhibitors (protein-protein interaction) | High-purity recombinant IRF3 monomer and phospho-mimetic mutants (S386D/S396D) sequence-verified for biochemical binding assays |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live IRF3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IRF3 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule modulators targeting the cGAS-STING-TBK1-IRF3 pathway. As first-generation therapies reach the clinic, the next wave of R&D is targeting the precise modulation of IRF3 dimerization and nuclear translocation to treat interferonopathies and cold tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | GlaxoSmithKline, Novartis | Systemic Lupus Erythematosus (SLE), AGS | Selectivity Assay (Need Mutant vs WT Proteins) |
| STING/IRF3 Agonists | Merck, Bristol Myers Squibb | Refractory Solid Tumors | Reporter Gene Assays (Need Lentivirus for Stable Cell Lines) |
| PROTAC / Degraders | Arvinas, Kymera Therapeutics | Autoimmune Diseases | Ubiquitination & Knockdown Validation (Need High-Purity Recombinant Protein & siRNA) |